Skip to main content
. 2021 Nov 26;13(23):5953. doi: 10.3390/cancers13235953

Figure 3.

Figure 3

Comparison of xenograft tumor growth in PGRMC1-intact and PGRMC1-deplete dsRed-SKOV-3 cells. Panel A shows a typical tumor derived from PGRMC1-intact dsRed-SKOV-3 cells, while a typical tumor derived from PGRMC1-deplete dsRed-SKOV-3 cells is shown in the inset of panel A. Images are shown at the same magnification (Peluso, unpublished data). The effect of cisplatin (CDDP 8 mg/kg body weight, i.p.) and P4 (1 mg/0.1 mL of oil, s.c.) on the percentage of apoptotic nuclei is shown in B. * indicates a significant difference from control (n = 24 to 65 tumors/treatment; p < 0.05). The microvasculature of tumors derived from PGRMC1-intact (C) and PGRMC1-deplete (D) dsRed-SKOV-3 cells is revealed by staining for the endothelial cell marker, CD31 (brown stain). (E) Expression of ARNT, HIF1A, and several ABC transporters are shown as a ratio of the mRNA levels in PGRMC1-deplete to PGRMC1-intact ovarian tumors. All changes in mRNAs are statistically significantly different (n = 4; p < 0.05). Images and graphs taken from Figure 6 of the article by Peluso et al. [4] with permission from CCC RightsLink.